Cutter & Co Brokerage’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Cutter & Co Brokerage’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,900	Closed	-$27.7K	–	224
2023 Q1	$27.7K	Buy	+10,900	New	+$21.5K	0.01%	211
2022 Q1	–	Sell	-10,900	Closed	-$49K	–	284
2021 Q4	$49K	Hold	10,900	–	–	0.01%	270
2021 Q3	$53K	Buy	10,900 +400	+4%	+$2.2K	0.01%	290
2021 Q2	$72K	Hold	10,500	–	–	0.02%	294
2021 Q1	$74K	Hold	10,500	–	–	0.02%	283
2020 Q4	$66K	Hold	10,500	–	–	0.02%	267
2020 Q3	$57K	Sell	10,500 -1,675	-14%	-$8.29K	0.02%	247
2020 Q2	$64K	Buy	+12,175	New	+$54.1K	0.02%	227
2018 Q3	–	Sell	-10,150	Closed	-$104K	–	290
2018 Q2	$104K	Buy	+10,150	New	+$115K	0.04%	234

Other funds holding PRTK

NAM

Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Cutter & Co Brokerage's PRTK Position: Q2 2023 in Review

Cutter & Co Brokerage sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2023, closing a stake of 10,900 shares — an estimated $27.7K sold.

Cutter & Co Brokerage first reported a position in PRTK in Q2 2018 and held it in 9 quarters. The position peaked at $104K in Q2 2018. 66 funds tracked by Wall St. Rank hold PRTK as of Q2 2023.

Cutter & Co Brokerage reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
Cutter & Co Brokerage sold 10,900 Paratek Pharmaceuticals, Inc. shares in Q2 2023, an estimated $27.7K.
Cutter & Co Brokerage first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2018 and held it in 9 quarters.
Cutter & Co Brokerage's Paratek Pharmaceuticals, Inc. position peaked at $104K in Q2 2018.
66 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2023.

Based on Cutter & Co Brokerage's 13F filing for Q2 2023, filed 1 Aug 2023.